Cellectis (NASDAQ:CLLS) Shares Cross Below 50 Day Moving Average – Should You Sell?

Cellectis S.A. (NASDAQ:CLLS) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.00 and traded as low as $1.75. Cellectis shares last traded at $1.83, with a volume of 1,172,743 shares traded.

Cellectis News Summary

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Robert W. Baird maintained an “outperform” rating despite reducing its price target from $10 to $8. The revised target remains substantially above recent trading levels, suggesting the firm still sees considerable upside if Cellectis successfully executes its new strategy. Benzinga analyst ratings article
• Neutral Sentiment: A Seeking Alpha analysis described the move into in vivo gene editing as an “all or nothing” pivot. The approach could create substantial value if successful, but investors should monitor clinical progress, funding needs and the company’s ability to establish credible development milestones. Seeking Alpha analysis
• Negative Sentiment: Citizens downgraded Cellectis following the strategic pivot, citing delayed catalysts and reduced visibility for the cancer pipeline. Wells Fargo also lowered its price target from $4 to $3 while retaining an “equal weight” rating, reinforcing cautious sentiment. Seeking Alpha downgrade report
• Negative Sentiment: Reports characterized the selloff as a roughly 40% decline, with Citizens warning that the pipeline realignment could postpone important value-driving events. The stock’s move below its 50-day moving average and unusually heavy trading volume indicate heightened technical and investor pressure. Yahoo Finance report

Analysts Set New Price Targets

Several brokerages have issued reports on CLLS. Wells Fargo & Company lowered their price target on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. Robert W. Baird lowered their target price on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Barclays lowered Cellectis from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $9.00 to $1.30 in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.46.

Cellectis Stock Performance

The firm has a market capitalization of $138.47 million, a price-to-earnings ratio of -2.12 and a beta of 2.92. The stock’s fifty day moving average is $2.97 and its two-hundred day moving average is $3.32. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Institutional Investors Weigh In On Cellectis

A hedge fund recently bought a new stake in Cellectis stock. Lido Advisors LLC bought a new stake in Cellectis S.A. (NASDAQ:CLLS) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.